Bihui Guo
Research Subjects
Research Interests
Bihui Guo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Bo Yao
Department of Pathology, Jinan University School of Medicine, Guangzhou, China
2 shared publications- Ping Li
Department of Pathology, Jinan University School of Medicine, Guangzhou, China
2 shared publications Gendie E. Lash
Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China
1 shared publication- Hanlin Shuai
Department of Obstetrics and Gynecology, First Affiliated Hospital of Jinan University, Guangzhou, China
1 shared publication Jingling Li
Department of Pathology, Jinan University School of Medicine, Guangzhou, China
1 shared publicationMinghua Wang
Department of Pathology, Longgang District People’s Hospital, The Second Affiliated Hospital of The Chinese University of Hong Kong, Shenzhen, China
1 shared publication
Latest Publications
- 8 September 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (11) , 2312-2322
Galaxamide Ameliorates Cisplatin-induced Uterine Injury via Anti‑inflammatory and Antiapoptotic Mechanisms in Mice
- 8 September 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (11) , 2312-2322
Galaxamide Ameliorates Cisplatin-induced Uterine Injury via Anti‑inflammatory and Antiapoptotic Mechanisms in Mice
- Open Access
- 12 November 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1273
Metformin protects against cyclophosphamide-induced ovarian fibrosis by MIF/CD74-mediated macrophage polarization
Background: Cyclophosphamide (CTX) -induced ovarian fibrosis is involved in premature ovarian failure (POF). While metformin has demonstrated anti-fibrotic properties, the mechanism by which it regulates fibroblast activation, the primary effector cells in fibrosis, remains unclear in POF. Methods: The therapeutic effects of metformin were investigated in CTX-treated mice and further explored its interaction with macrophage-fibroblast crosstalk using an in vitro co-culture system. Results: RNA sequencing revealed that metformin suppressed the MIF/CD74 signaling pathway, which was significantly activated by CTX in ovarian tissues. In vitro, CTX increased the CD86+/CD206 + macrophage ratio via NF-κB pathway activation, indicating altered macrophage polarization. Metformin or the MIF inhibitor ISO-1 reversed this polarization imbalance, thereby attenuating fibroblast activation and extracellular matrix (ECM) production in co-culture models. Additionally, CD74 knockdown in fibroblasts downregulated ECM-related genes and inhibited MAPK/JNK signaling, whereas CD74 overexpression exacerbated the fibrotic responses. Conclusion: These findings highlight a novel mechanism by which metformin alleviates CTX-induced ovarian fibrosis by targeting the MIF/CD74 axis to reprogram macrophage-fibroblast communication, suggesting metformin as a protective adjuvant to improve ovarian health during chemotherapy.
- 12 November 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1273
Open AccessMetformin protects against cyclophosphamide-induced ovarian fibrosis by MIF/CD74-mediated macrophage polarization
Background: Cyclophosphamide (CTX) -induced ovarian fibrosis is involved in premature ovarian failure (POF). While metformin has demonstrated anti-fibrotic properties, the mechanism by which it regulates fibroblast activation, the primary effector cells in fibrosis, remains unclear in POF. Methods: The therapeutic effects of metformin were investigated in CTX-treated mice and further explored its interaction with macrophage-fibroblast crosstalk using an in vitro co-culture system. Results: RNA sequencing revealed that metformin suppressed the MIF/CD74 signaling pathway, which was significantly activated by CTX in ovarian tissues. In vitro, CTX increased the CD86+/CD206 + macrophage ratio via NF-κB pathway activation, indicating altered macrophage polarization. Metformin or the MIF inhibitor ISO-1 reversed this polarization imbalance, thereby attenuating fibroblast activation and extracellular matrix (ECM) production in co-culture models. Additionally, CD74 knockdown in fibroblasts downregulated ECM-related genes and inhibited MAPK/JNK signaling, whereas CD74 overexpression exacerbated the fibrotic responses. Conclusion: These findings highlight a novel mechanism by which metformin alleviates CTX-induced ovarian fibrosis by targeting the MIF/CD74 axis to reprogram macrophage-fibroblast communication, suggesting metformin as a protective adjuvant to improve ovarian health during chemotherapy.